SARS-CoV-2 third vaccine immune response in MS patients treated with ocrelizumab. Brill L, Raposo C, Rechtman A, Zveik O, et al. Ann Neurol 2022 Mar 4. doi: 10.1002/ana.26343.

Read + Share

Amedeo Smart

Independent Medical Education

Brill L, Raposo C, Rechtman A, Zveik O, et al. SARS-CoV-2 third vaccine immune response in MS patients treated with ocrelizumab. Ann Neurol 2022 Mar 4. doi: 10.1002/ana.26343.
PMID: 35243687